SecBot SecBot
Insider Cluster (2 insiders) ·Filed Jun 5, 2026

XERS

Xeris Biopharma Holdings, Inc.
NEUTRAL
Impact 3/10
Horizondays Processed5mo ago
Insider cluster: 2 insiders, $192K total
Actionable Insight • Neutral

The selling is immaterial in size and lacks C-suite participation, suggesting routine portfolio management. The larger director grants on June 4 signal board alignment. Monitor for any upcoming earnings or pipeline catalysts that could move the stock, but this cluster alone does not warrant action.

DirectionNeutral
Confidencemedium
Horizondays

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$6.24
T+0 close · Jun 5, 2026 · via day close
Latest settled
+35.10%
T+60 · $8.43
Vs SPY
+32.04%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 8 $6.24entry
  2. T+1 · 5mo ago +4.17%α +4.46% · $6.50
  3. T+5 · 5mo ago +10.26%α +8.14% · $6.88
  4. T+20 · 4mo ago +34.13%α +32.50% · $8.37
  5. T+60 · 3mo ago +35.10%α +32.04% · $8.43

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Two Xeris insiders (Director Persky and officer Hecht) sold a combined $192K in open-market sales over a 3-day window. The sales are modest relative to the $1.1B market cap (0.017%), and the cluster includes multiple director grants/awards on June 4 that offset the selling. The selling is likely liquidity-driven and not indicative of bearish conviction.

Key Financial Metrics

Direction
selling
Total Value
$192.0K
Insiders
2

Key Facts

  • Director Persky sold 15,500 shares at $5.90 for $91K on June 3
  • Officer Hecht sold 16,667 shares at $6.06 for $101K on June 1
  • Total open-market sales: $192K, or ~0.017% of $1.1B market cap
  • On June 4, four directors received grants/awards totaling $812K in value (non-cash plus deemed cash at $6.15)
  • No C-suite executives (CEO/CFO) participated in the selling

Financial Impact

Open-market sales of $192K represent 0.017% of market cap, trivial

insider ownership

Risk Factors

  • Insider selling could accelerate if stock price appreciates further
  • No material negative signal from this cluster, risk of over-interpreting noise

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
85% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-XERS-1780698596780

US Market Status

Market Closed · Opens in 5h 53m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 5, 2026